Canaccord analyst Sumant Kulkarni downgraded Zynerba Pharmaceuticals to Hold from Buy with a price target of $1.11, down from $10, after the company entered into an agreement to be acquired by Harmony Biosciences (HRMY). The stock is no longer trading on fundamentals, the analyst tells investors in a research note.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on ZYNE:
- Zynerba downgraded to Neutral from Buy at H.C. Wainwright
- Zynerba downgraded to Neutral from Buy at Ladenburg
- Zynerba Pharma (NASDAQ:ZYNE) Skyrockets 3x on Acquisition by Harmony Bio (NASDAQ:HRMY)
- Harmony Biosciences to acquire Zynerba
- HARMONY BIOSCIENCES TO ACQUIRE ZYNERBA PHARMACEUTICALS, INC.
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue